Overview

Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis

Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of this dose-escalating trial is to assess the safety and tolerability of multiple doses of NNC0114-0006 in subjects with rheumatoid arthritis (RA).
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S